Tumour mutational burden in treatment-resistant tumours

Lancet Oncol. 2020 Dec;21(12):e551. doi: 10.1016/S1470-2045(20)30617-3.

Authors

Wei Nie¹, Jie Qian², Bo Zhang¹, Hua Zhong¹, Baohui Han³

Affiliations

¹ Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 20030, China.
² Department of Emergency Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 20030, China.
³ Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 20030, China. Electronic address: 18930858216@163.com.

PMID: 33271108
DOI: 10.1016/S1470-2045(20)30617-3

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Biomarkers, Tumor
Humans
Neoplasms*
Prospective Studies

Substances

Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
pembrolizumab